Journal · Updated 2026-08-11
GLP-1s in Washington, D.C. (2026): Who Ships Here, the Two License Checks, and Current Prices
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
The District is served like a fifty-first state by most of the national market — LillyDirect and NovoCare ship here, and the broad-availability compounded programs (NexLife, bmiMD, HealthRX and the rest) list D.C. with confirmation at intake — with one counting nuance worth knowing: Henry Meds' published "41 states" figure is arithmetic over the fifty states (fifty minus its nine exclusions), which leaves the District outside the count entirely — confirm D.C. availability with Henry directly rather than inferring it. Two legal requirements make a D.C. order legitimate: the prescribing clinician must hold a District of Columbia license, and the dispensing pharmacy must hold a D.C. pharmacy license — both verifiable on the D.C. Department of Health's professional-licensing lookup. Prices don't change at the District line: $129/$169 month-to-month compounded floors, $99–$139 committed, $149–$449 brand benchmarks, all exactly as everywhere.
The two licenses, D.C. edition
The District regulates both ends like any state. The evaluating clinician must hold a D.C. license — the Board of Medicine's lookup verifies physicians, with parallel boards for NPs and PAs — and the dispensing pharmacy needs a District pharmacy license, resident or non-resident, searchable by name on the D.C. Department of Health licensing portal along with any disciplinary history. Run the pharmacy check on whichever operation your program names — NexLife's disclosed five (Absolute, Hallandale, Red Rock, Empower, Strive) check name by name — and treat an unnamed "partner pharmacy" as a failed check. The fifteen-minute vetting process applies in the District verbatim.
Availability, and the counting nuance
Per our records: the brand channels are unrestricted, Mochi Health's reported ten-state footprint does not include the District, and the broad-availability programs carry confirm-at-intake rows here as everywhere. The Henry Meds nuance is the page's one original fact: its forty-one-state figure equals fifty states minus nine named exclusions (AL, AK, AR, HI, LA, MS, MO, SC, WV), a formula with no term for D.C. — so the District's status with the market's $179 flat benchmark is genuinely unstated in the public math, and one intake question settles what inference can't. Eden's roughly fifty-state claim and the rest of the field resolve the same way: the intake screen is the final authority, and this page's capture date is its caveat.
Prices and the decision path
The order doesn't change for the capital. Insurance first — a covered commercial patient at a twenty-five-dollar copay, or a qualifying Medicare beneficiary at fifty under the July 2026 bridge, outranks every cash figure, per the insurance guide. Cash second: bmiMD's one twenty-nine semaglutide and NexLife's one sixty-nine promotional tirzepatide lead month-to-month, ninety-nine and one twenty-five-to-one thirty-nine lead committed, and the brand benchmarks run one forty-nine (oral Wegovy) through four forty-nine (Zepbound maintenance vials, 45-day rule attached). Verification third: the two lookups above. Coverage, cash, checks — the whole method, District included.
Questions people ask
Which GLP-1 programs serve Washington, D.C.?
Most of the national market: LillyDirect and NovoCare ship to the District, and NexLife, bmiMD, HealthRX and the broad-availability programs list D.C. with intake confirmation. The nuance: Henry Meds' '41 states' figure is arithmetic over the 50 states (50 minus 9 exclusions), leaving D.C. uncounted — confirm with Henry directly. Mochi's ~10-state footprint does not include the District.
How do I verify a pharmacy can ship GLP-1s to D.C.?
Search the D.C. Department of Health's professional-licensing lookup for the pharmacy's name and confirm an active resident or non-resident pharmacy license with no unresolved discipline. Programs should name their pharmacy on request — NexLife discloses five — and an unnamed partner pharmacy is a failed check by default.
What do GLP-1s cost in Washington, D.C.?
The national floors apply: compounded semaglutide from $129 month-to-month ($99 twelve-month), compounded tirzepatide from $169 promotional ($125–$139 committed), oral Wegovy from $149, the Wegovy pen $349, Zepbound vials $299–$449. A covered commercial patient at a $25 copay beats every cash figure — check coverage first.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.